摘要
目的:研究氯诺昔康治疗类风湿关节炎和骨性关节炎的疗效及安全性。方法:类风湿关节炎(34例)和骨性关节炎(48例)所致膝关节疼痛患者分别随机双盲分成2组,试验组(n=41)行膝关节腔注射氯诺昔康(8mg,每周1次),对照组(n=41)用安慰剂,疗程为3周。对二药治疗前后的疼痛指数进行比较。结果:试验组和对照组在治疗3周后的平均疼痛指数分别减少31.80和8.20(P<0.05),显示氯诺昔康对关节炎的疼痛有显著疗效。2组不良事件发生率分别为7.31%和4.87%,均无严重不良事件发生。结论:氯诺昔康对类风湿关节炎和骨性关节炎具有良好的镇痛抗炎作用,且耐受性良好。
Objective:To study the efficacy and safety of lornoxicam in treatment of rheumatoid arthritis and osteoarthritis. Methods: The randomized and double blind study was conducted in 34 patients with rheumatoid arthritis and 48 patients with osteoarthritis.They were randomly divided to re-ceive lornoxicam 8mg/week for 3 weeks or placebo for 3 weeks. Results: After treatment, the mean Huskinssion's VAS was reduced by 31. 80 for active group and 8. 20 for control group and the incidence of ADRs was 7.31% for active group and 4. 87% for control group. Conclusion:Lornoxicam is effective in treatment of rheumatoid arthritis and osteoarthritis with mild adverse reactions.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2004年第6期562-564,共3页
Chinese Journal of New Drugs
